Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: July 2, 2020

DrugPatentWatch Database Preview


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Tradename: LEVEMIR PENFILL
Suppliers: see list1
Recent Clinical Trials: See clinical trials for LEVEMIR PENFILL
Recent Clinical Trials for LEVEMIR PENFILL

Identify potential brand extensions & biosimilar entrants

Medical University of GrazPhase 1

See all LEVEMIR PENFILL clinical trials

Company Disclosures: US Patents for LEVEMIR PENFILL

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novo Nordisk Inc LEVEMIR PENFILL insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536 004 2005-06-16   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2014-04-08 DISCN company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for LEVEMIR PENFILL

These patents were identified by searching patent claims

Supplementary Protection Certificates for LEVEMIR PENFILL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C990042 Netherlands   Start Trial PRODUCT NAME: INSULIN ASPART; REGISTRATION NO/DATE: EU/1/99/119/001 - EU/1/99/119/005 19990907
SPC/GB99/045 United Kingdom   Start Trial SPC/GB99/045: 20060829, EXPIRES: 20110828
99C0044 Belgium   Start Trial PRODUCT NAME: INSULIN-ASPART; NAT. REGISTRATION NO/DATE: EU/1/99/119/001 19990907; FIRST REGISTRATION: CH 55045 01 19990615
SZ 50/1999 Austria   Start Trial PRODUCT NAME: INSULIN ASPART
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.